ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Augmenting the Endogenous RBM3 Response Protects Against Burn-Induced Acute Kidney Injury by Enhancing Macrophage-Mediated Resolution of Inflammation.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The regulatory mechanisms underlying M1/M2 macrophage polarization and efferocytosis in acute kidney injury (AKI) remain poorly understood. This study aimed to investigate the mechanism by which RBM3 modulates macrophage function to alleviate burn-induced AKI. A standardized scald burn model was established in rats by dorsal immersion in 100°C water for 15 s. Renal function and histopathology were evaluated at 24, 48, and 72 h post-injury through serum biochemistry and hematoxylin and eosin (H&E) staining. RBM3 expression was analyzed by qRT-PCR, Western blot, immunohistochemistry, and flow cytometry. Adenoviral RBM3 was administered to AKI rats, followed by a comprehensive assessment including renal function tests, H&E/TUNEL staining, KIM-1 immunofluorescence, macrophage polarization analysis (M1/M2 markers), and cytokine profiling (IL-6, IL-1β, and TNF-α). Single-cell RNA sequencing identified differentially expressed genes, particularly Slfn4, validated via in vitro knockdown and dual RBM3/Slfn4 interference experiments in bone marrow-derived macrophages to assess polarization and efferocytosis. Peak AKI severity occurred at 48 h post-burn, coinciding with dynamic RBM3 expression. RBM3 overexpression significantly improved renal function, attenuated tissue damage, reduced inflammation as evidenced by decreased levels of IL-6, IL-1β, and TNF-α, promoted M2 polarization characterized by increased Arg1 expression and decreased CD86 and iNOS levels, and enhanced efferocytosis. Slfn4 knockdown replicated the protective effects of RBM3, while RBM3 inhibition exacerbated M1 polarization, effects that were rescued by concurrent Slfn4 suppression. RBM3 ameliorates burn-induced AKI by downregulating Slfn4 to drive a pro-resolving macrophage program. The RBM3-Slfn4 axis may represent a potential therapeutic target for AKI management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.